Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wesley Hayes

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Kidney International Reports|July 31, 2024
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical TrialJeffrey M Saland, John C Lieske, Jaap W Groothoff, et al.
Kidney International|August 25, 2022
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2Michelle A Baum, Craig Langman, Pierre Cochat, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 29, 2021
Acute paediatric kidney replacement therapies in Europe: demographic results from the EurAKId RegistryIsabella Guzzo, Lara de Galasso, Aysun Karabay Bayazit, et al.
Kidney International Reports|October 21, 2024
Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1Lisa J Deesker, Hazal A Karacoban, Elisabeth L Metry, et al.
Pediatric Nephrology (Berlin, Germany)|July 18, 2024
Factors influencing circuit lifetime in paediatric continuous kidney replacement therapies - results from the EurAKId registryAnna Deja, Isabella Guzzo, Andrea Cappoli, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Kidney International|June 15, 2026
Real-world outcomes of pegcetacoplan treatment in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritisGiulia Bassanese, Ariel Martje Weingarten, Maria Cristina Mancuso, et al.
Orphanet Journal of Rare Diseases|February 3, 2026
Adolescents' experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growthVrinda Saraff, Pedro Arango-Sancho, Justine Bacchetta, et al.
Kidney International Reports|March 8, 2022
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A Hulton, Jaap W Groothoff, Yaacov Frishberg, et al.
Journal of Nephrology|April 6, 2019
Acute dialysis in children: results of a European surveyIsabella Guzzo, Lara de Galasso, Sevgi Mir, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Kidney International Reports|July 31, 2024
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical TrialJeffrey M Saland, John C Lieske, Jaap W Groothoff, et al.
Kidney International|August 25, 2022
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2Michelle A Baum, Craig Langman, Pierre Cochat, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 29, 2021
Acute paediatric kidney replacement therapies in Europe: demographic results from the EurAKId RegistryIsabella Guzzo, Lara de Galasso, Aysun Karabay Bayazit, et al.
Kidney International Reports|October 21, 2024
Intrafamilial Disease Heterogeneity in Primary Hyperoxaluria Type 1Lisa J Deesker, Hazal A Karacoban, Elisabeth L Metry, et al.
Pediatric Nephrology (Berlin, Germany)|July 18, 2024
Factors influencing circuit lifetime in paediatric continuous kidney replacement therapies - results from the EurAKId registryAnna Deja, Isabella Guzzo, Andrea Cappoli, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Kidney International|June 15, 2026
Real-world outcomes of pegcetacoplan treatment in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritisGiulia Bassanese, Ariel Martje Weingarten, Maria Cristina Mancuso, et al.
Orphanet Journal of Rare Diseases|February 3, 2026
Adolescents' experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growthVrinda Saraff, Pedro Arango-Sancho, Justine Bacchetta, et al.
Kidney International Reports|March 8, 2022
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A Hulton, Jaap W Groothoff, Yaacov Frishberg, et al.
Journal of Nephrology|April 6, 2019
Acute dialysis in children: results of a European surveyIsabella Guzzo, Lara de Galasso, Sevgi Mir, et al.
Pageof 6